Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
| | |||
Aegis |
Undisclosed company |
The unnamed partner licensed rights to use Intravail delivery technology with undisclosed pediatric therapeutics |
The Intravail technology allows intranasal delivery of peptide and protein therapeutics; terms of the deal were not disclosed (8/1) |
Aegis |
Intranasal Technology Inc.* |
Expanded a deal to apply Aegis' Intravail delivery technology to intranasal heparin and beta-interferon |
Terms of the deal were not disclosed (6/20) |
Agilix Corp.* |
Protana Inc.* |
Protana got a nonexclusive license to Agilix's i-PROT proteomics technology |
Protana will use the technology in its proteomic services, including biomarker discovery; terms were not disclosed (7/21) |
Aldevron LLC* |
CytoGenix Inc. (OTC BB:CYGX) |
Aldevron will test the activity of a CytoGenix DNA vaccine against hepatitis B |
Aldevron will use use its Genetic Immunization and Antibody technology in the effort; terms were not disclosed (8/2) |
Alkermes |
Cephalon Inc. (CEPH) |
Agreement for the commercialization of Vivitrex; Alkermes would get $110M more upon FDA approval, filed an NDA for the alcohol-dependence drug in March |
Alkermes gets $160M in cash up front; it and could get up to another $220M in sales-based milestones; they would share profits on a 50-50 basis (6/24) |
Alnylam |
MWG Biotech AG (Germany; FSE:NWUG) |
MWG got nonexclusive rights to provide research products and services under Alnylam RNA interference patents |
Terms of the license to the Kreutzer- Limmer patent family were not disclosed (7/25) |
Alnylam |
Nastech Pharmaceutical Co. Inc.(NSTK) |
Nastech got an exclusive license to develop and sell RNAi therapeutics directed against TNF-alpha |
Alnylam gets up-front and annual payments and is entitled to milestone payments and royalties on sales of covered products (7/20) |
Alnylam |
Eurogentec SA* (Belgium) |
Eurogentec got nonexclusive rights to provide research products and services under Alnylam RNA interference patents |
The Kreutzer-Limmer patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (7/12) |
Aphton Corp. |
VaxGen Inc. (VXGN) |
VaxGen's South Korean joint venture Celltrion got rights to the cancer antibody IGN311 in certain Asian countries, including Japan |
Igeneon AG, Aphton's subsidiary in Austria, potentially will get $6M in milestone payments and royalties on sales; Celltrion also will provide development and manufacturing services related to the product (7/25) |
Array |
InterMune Inc. (ITMN) |
Extended and expanded a 2002 deal to develop small-molecule inhibitors of the hepatitis C virus NS3/4 protease |
InterMune is funding preclinical efforts at Array and would develop and sell resulting products; Array is entitled to milestone and royalty payments (7/19) |
AutoGenomics |
Targeted Molecular Diagnostics LLC* |
Three-year deal to develop cancer biomarkers on the Auto-Genomics Infiniti platform |
Terms of the deal were not disclosed (7/27) |
Avalon |
MedImmune Inc. (MEDI) |
Collaboration to discover and develop small-molecule drugs in the area of inflammatory disease |
Avalon will identify lead compounds; Med- Immune has all other responsibilities; Avalon gets an up-front payment, R&D support and potential milestone and royalty payments (6/20) |
BioRap |
BioLineRx Ltd.* (Israel) |
BioLineRx licensed BL-2030, a soluble receptor that targets cancer cells |
Terms of the exclusive, worldwide license were not disclosed (6/20) |
Banyan |
Biosite Inc. (BSTE) |
Deal to review cerebrovascular injury targets discovered with Banyan's animal model of cerebral injury |
Biosite may select targets that Banyan nom-inates, and then would make antibodies to those targets, which would be used to create assays; terms of the deal were not disclosed (8/1) |
Calando |
Benitec Ltd. (Australia; ASX: BLT) |
Benitec got exclusive rights to use polymeric nucleic acid delivery technology with its RNAi-based therapeutic for hepatitis C virus |
Calando gets an up-front payment and potential milestone and royalty payments related to the HCV drug (6/21) |
Carna |
Rigel Pharmaceuticals Inc. (RIGL) |
Service agreement in the field of structure-based drug design |
Carna and Crystal will provide services to Rigel under undisclosed terms (6/20) |
Cellectis SA* |
Ozgene Pty. Ltd.* (Australia) |
Ozgene got a nonexclusive license to a patent covering replacement or insertion of a gene in a eukaryotic genome |
Ozgene got rights related to the creation, development and sales of knock-in mice; terms of the deal were not disclosed (7/12) |
Cellectis SA* |
Xenogen Corp. (XGEN) |
Xenogen got a nonexclusive license to a patent covering replacement or insertion of a gene in an eukaryotic genome |
Xenogen will use the technology for creating knock-in mice; terms of the deal were not disclosed (6/29) |
ChemDiv Inc.* |
Euroscreen SA* (Belgium) |
Partnership to discover and develop drugs against GPCR family chemokine targets |
They intend to combine expertise in the effort, and share income from partnering clinical and preclinical candidates (7/1) |
Chiron Corp. |
OraSure Technologies Inc. (OSUR) |
OraSure got nonexclusive rights to certain patents covering hepatitis C virus |
OraSure intends to use the technology in a diagnostic product; it will make up-front and royalty payments for the license (8/2) |
CiVentiChem |
Tranzyme Pharma Inc.* |
CiVentiChem will provide medicinal chemistry and other services for Tranzyme |
The goal is to advance development of Tranzyme's small-molecule products; terms of the deal were not disclosed (6/29) |
Compugen Ltd. |
Biosite Inc. (BSTE) |
Biosite got rights to develop immunoassay-based diagnostics using biomarkers discovered by Compugen |
Compugen is entitled to milestone payments and royalties from resulting prod- ucts; Compugen retains therapeutic rights, and would pay Biosite milestones and royalties on those products (6/20) |
Crucell NV |
Chiron Corp. (CHIR) |
Chiron got rights to test the PER.C6 cell line for use in manufacturing a prophylactic hepatitis C vaccine candidate |
Terms of the deal were not disclosed (8/16) |
Crucell NV |
Symphogen A/S* (Denmark) |
Symphogen got rights to use the PER.C6 cell line for producing its recombinant polyclonal antibodies |
Symphogen will pay a signing fee and annual maintenance fees; further terms were not disclosed (7/15) |
DeveloGen |
Debiopharm SA* (Switzerland) |
Debiopharm got rights to develop PTR- 62, a peptide drug for the treatment of myasthenia gravis |
Debiopharm intends to out-license the product later; DeveloGen is entitled to milestone and royalty payments (8/16) |
DxS Ltd.* |
Cepheid Inc. (CPHD) |
Cepheid got rights to use Scorpions probe technology in a number of applications |
Cepheid intends to apply the technology to industrial markets; its license excludes clinical diagnostics, wine production and detection of chemicals used in agriculture (7/20) |
Essential |
Prolysis Ltd.* (UK) |
They extended collaboration on advancing Prolysis' bacterial cell biology and antibiotic development programs |
They now will focus on out- or in-licensing opportunities; terms of the deal were not disclosed (6/17) |
Europroteome |
Miraculins Inc. (Canada; TSE:MOM) |
Miraculins purchased all rights to a number of patents and discoveries related to the diagnosis and treatment of cancers |
Europroteome is in receivership; Miraculins has no further milestone or royalty obligations in the deal (6/22) |
Evolva Biotech |
AnalytiCon Discovery GmbH* (Germany) |
Collaboration to generate and optimize nuclear receptor agonists and related compounds |
Evolva will create and optimize the agonists; AnalytiCon will de-replicate, identify and scale-up the compounds; terms of the deal were not disclosed (6/30) |
Galapagos NV |
Celera Genomics Group (NYSE:CRA) |
Galapagos will provide technology and adenoviral reagents for Celera research |
Galapagos will construct recombinant adenoviruses harboring genes selected by Celera; it will receive undisclosed payments for the work (6/20) |
GeneThera |
Xpention Genetics Inc. (OTC BB:XPNG) |
GeneThera will provide research services for development of a cancer detection test in animals and humans |
Under one contract GeneThera will get $20,000 per month for one year to develop a test for animals; GeneThera will get $10,000 per month under a second contract to extend the technology into human testing (7/19) |
Genmab A/S |
Serono SA (Switzerland; NYSE:CRA) |
Serono got worldwide rights to HuMax-CD4, a fully human monoclonal antibody for treating T-cell lymphomas that's in Phase III trials |
Genmab gets a $20M license payment, and a $50M equity investment from Serono at a premium; Genmab could get up to $145M more in regulatory and sales milestones, as well as royalties on resulting sales (8/18) |
Hyalose LLC* |
Meditech Research Ltd. (Australia; ASX:MTR) |
Collaboration to evaluate hyaluronic acid molecules for their ability to act as targeting agents in drug delivery systems |
The HA molecules are produced using recombinant technology developed at the University of Oklahoma and licensed to Hyalose; terms of the deal were not disclosed (7/7) |
Iconix |
Neurocrine |
Iconix will provide chemo-genomic analyses on candidate compounds from Neurocrine |
Iconix will apply its DrugMatrix technology to at least 12 Neurocrine compounds; terms of the deal were not disclosed (7/12) |
Icoria Inc. |
Isis Pharmaceuticals Inc. (ISIS) |
Agreement to identify biomarkers of toxicity in animal models |
Icoria will use its metabolomics platform to characterize differences in biochemical profiles between treated and untreated animal subjects and to identify those biochemicals that are specifically affected by treatment (8/23) |
ImmunoGen |
Genentech Inc. (NYSE:DNA) |
Genentech got exclusive rights to use ImmunoGen's Tumor-Activated Prodrug technology with antibodies to an undisclosed target |
ImmunoGen gets a $1M license payment and is entitled to milestone and royalty payments; Genentech now has taken three licenses to the TAP technology (7/26) |
Jurilab Ltd.* |
Nanogen Inc. (NGEN) |
Nanogen acquired certain rights to develop diagnostic products based on genes and markers discovered by Jurilab; it also will distribute Jurilab's pharmaco- genomic products and services |
Nanogen made a €1.25M investment for a stake of less than 20% in Jurilab, and will invest that much again in six months; Nanogen also got an option to purchase all of Jurilab; terms were not disclosed (7/26) |
Large Scale |
BioCatalytics Inc.* |
Collaboration to apply their technologies to develop improved enzymes for chemical synthesis |
LSBC gets a license fee for use of its protein- improvement technologies, and would get royalties on any resulting sales (8/17) |
Lexicon |
XOMA Ltd. (XOMA) |
Collaboration to jointly develop and market antibody drugs for certain targets discovered by Lexicon |
Lexicon will submit targets and XOMA will generate antibodies to them; costs and profits will be allocated 65% to Lexicon and 35% to XOMA; XOMA will have manufactu- ring responsibility (6/21) |
Medarex Inc. |
Genmab A/S (Denmark; CSE:GEN) |
Genmab licensed European and Asian rights to use UltiMAb technology in anti-bodies raised against the CD4 antigen, including HuMax-CD4 |
Medarex gets $2M up front and is entitled to milestone and license fee payments up to $12.5M; it also would get royalties that could reach double digits; Genmab now has worldwide rights to HuMax-CD4 (6/30) |
Mimitopes Pty. |
Phylogica Ltd. (Australia; ASX:PYC) |
Partnership to pool technologies to develop next- generation peptide drugs |
They will use Phylogica's Phylomer and Mimitopes' Synthase technologies in the effort; terms of the deal were not disclosed (8/15) |
Neovacs SA* |
Debiopharm SA* (Switzerland) |
Collaboration to develop Neovacs' tumor necrosis factor alpha kinoid and related programs |
Debiopharm will fund the program, and make up-front and milestone payments in cash and equity; Neovacs also would be entitled to royalties on sales (6/27) |
NovaThera |
Pharming Group NV (the Nertherlands; Euronext:PHARM) |
Collaboration to combine NovaThera's biomaterial products with Pharming's recombinant proteins |
NovaThera is entitled to milestone and royalty payments in the deal; Pharming gets rights to resulting products (7/12) |
Odyssey |
Lexicon Genetics Inc. (LEXG) |
Odyssey will characterize the pathway activity of certain Lexicon compounds in human cells |
Terms of the deal were not disclosed (7/20) |
Oxxon |
Bavarian Nordic A/S (Denmark; CSE:BAVA) |
Cross-licensing deal covering modified vaccinia ankara and PrimeBoost technologies |
Oxxon got certain rights to MVA technology and Bavarian Nordic got rights to PrimeBoost; each would pay the other royalties on any resulting sales (7/1) |
Pharming |
AgResearch Ltd.* (New Zealand) |
Partnership under which AgResearch will produce recombinant human lactoferrin for Pharming |
AgResearch got a research license to technology for producing recombinant proteins; Pharming will have the first right to review products from AgResearch's protein discovery and R&D projects (6/30) |
Protein Design |
Biogen Idec Inc. (BIIB) |
Deal to jointly develop and market three Phase II PDL antibodies: daclizumab, M200 (volociximab) and HuZAF (fontolizumab) |
PDL gets $40M up front and a $100M equity investment; it also could earn up to $560M in development milestones and $100M in commercialization milestones; they will share costs and profits in the U.S. and Europe, and PDL would get royalties elsewhere (8/2) |
Protein Design |
Genentech Inc. (NYSE:DNA) |
Genentech sublicensed rights to antibody-drug conjugate technology against the PR1 antigen,which has applications in prostate cancer |
PDL, which got certain sublicensing rights from Seattle Genetics Inc., is entitled to an up-front licensing fee along with potential milestone and royalty payments (6/22) |
Provid |
Immune Control Inc.* |
Collaboration to develop lead compounds for diseases with immunological causes |
Provid will use its technologies to develop the lead compounds; terms of the deal were not disclosed (6/17) |
RheoGene |
Cellumen Inc.* |
Cellumen got nonexclusive rights to use RheoGene's RheoSwitch and RheoPlex technologies |
Cellumen intends to develop systems cell biology screening products and offer them to drug developers; they also will develop and validate mammalian cell lines; terms were not disclosed (7/26) |
Santhera |
Biovitrum AB* (Sweden) |
Biovitrum got worldwide rights to Santhera's DPP-IV inhibitor program for treating Type II diabetes and other metabolic diseases |
Santhera gets €4M up front, and gets a certain percentage of future revenues, which could include milestones and royalties from sublicenses (8/17) |
Scancell Ltd.* |
GTC Biotherapeutics Inc. (GTCB) |
Collaboration centered on Scancell's SC101 anticancer monoclonal antibody, which targets Lewis y/b |
They will evaluate expression of the MAb using GTC's transgenic production platform, an effort that could lead to a collaboration on clinical development; terms were not disclosed (7/28) |
Seattle |
Progenics Pharmaceuticals Inc. (PGNX) and Cytogen Corp. (CYTO) |
PSMA Development Co. got rights to use antibody- drug conjugate technology for targeting prostate-specific membrane antigen |
PSMA Development Co. is a joint venture between Progenics and Cytogen; Seattle Genetics gets a $2M access fee, annual maintenance fees and research support payments, as well as potential milestones and royalties (6/20) |
Serologicals |
CXR Biosciences Ltd.* (UK) |
Collaboration to establish a battery of in vitro screens for improving selection of candidate drug molecules |
Serologicals subsidiary Upstate Group will work with CXR in the effort; terms of the deal were not disclosed (6/22) |
Sonus |
ImaRx Therapeutics Inc.* |
ImaRx got a license to fluorocarbon-based oxygen- delivery technology |
ImaRx's sublicense on four patents is exclusive; Sonus would get royalties on any resulting sales (7/11) |
SR Pharma |
Introgen Therapeutics Inc. (INGN) |
Introgen is supporting work at SR Pharma through a $3M investment |
Introgen gained an 8.3% stake in SR Pharma and expanded its presence into Europe; further terms were not disclosed (7/28) |
StemCells |
ReNeuron Holdings plc* (UK) |
ReNeuron licensed rights to use c-mycER conditionally immortalized adult human neural stem cell technology |
StemCells got an equity interest in ReNeuron and a cross- icense to exclusively use ReNeuron's technology for certain diseases and conditions; each would pay the other milestones and royalties on resulting products (7/6) |
Symphogen |
Cambridge Antibody Technology Group plc (UK; CATG) |
Patent license agreement giving Symphogen access to CAT's antibody phage display patents for research purposes and to develop and commercialize antibody products |
Symphogen made an up-front payment and exercised its first option to develop and commercialize Sym001 for idiopathic thrombocytopenic purpura and hemolytic disease of newborns; as a result, Symphogen paid a product license fee, and may make future milestone and royalty payments to CAT (8/23) |
Tolerance |
MacroGenics Inc.* |
MacroGenics acquired an anti-CD3 monoclonal antibody for treating Type I diabetes and other autoimmune diseases |
The product has been in a Phase I trial; terms of the deal were not disclosed (7/18) |
Valentis Inc. |
Biolitec AG (Germany; FSE:BIB) |
Biolitec got worldwide rights to use pegylated liposomal technology from Valentis to develop new drug formulations |
Valentis gets an up-front payment and is eligible to receive milestone payments and royalties on any resulting sales (6/22) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | |||
To read more on related topics, click on one of the words below.